
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings is a leading regenerative medicine company with a strong portfolio of products focused on advanced wound care and surgical/sports medicine markets. Multiple regulatory pathways, including PMA, 510k, and 361 approvals, demonstrate a differentiated approval status and potential for market growth. With a robust clinical pipeline, strong executive leadership, and solid financials, Organogenesis is well-positioned for future success and potential acquisition as the industry consolidates.
Bears say
Organogenesis Holdings is facing major headwinds in the advanced wound care market due to recent reimbursement changes and market consolidation. These factors are causing uncertainty and confusion among providers, leading to a significant decline in revenue and profitability. While the company has a strong portfolio of products and potential opportunities for growth, it will take time for the market to stabilize and for the company to regain positive momentum. Additionally, the potential approval of their newest product, ReNu, presents a promising opportunity but remains uncertain and will likely not have a significant impact on the company's near-term financials. As a result, there is a high level of risk and limited visibility for Organogenesis Holdings, leading to a negative outlook for their stock.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares